AIM: To evaluate the clinical usefulness of Daikenchuto (DKT) in hepatecomized patients. METHODS: Twenty patients were enrolled with informed consent. Two patients were excluded because of cancelled operations. The re...AIM: To evaluate the clinical usefulness of Daikenchuto (DKT) in hepatecomized patients. METHODS: Twenty patients were enrolled with informed consent. Two patients were excluded because of cancelled operations. The remaining 18 patients were randomly chosen for treatment with DKT alone or combination therapy of DKT and lactulose (n = 9, each group). Data were prospectively collected. Primary end points were Visual Analogue Scale (VAS) score for abdominal bloating, total Gastrointestinal Symptoms Rating Scale (GSRS) score for abdominal symptoms, and GSRS score for abdominal bloating. RESULTS: The VAS score for abdominal bloating and total GSRS score for abdominal symptoms recovered to levels that were not significantly different to preoperative levels by 10 d postoperation. Combination therapy of DKT and lactulose was associated with a significantly poorer outcome in terms of VAS and GSRS scores for abdominal bloating, total GSRS score, and total daily calorie intake, when compared with DKT alone therapy. CONCLUSION: DKT is a potentially effective drug for postoperative management of hepatectomized patients, not only to ameliorate abdominal bloating, but also to promote nutritional support by increasing postoperative dietary intake.展开更多
Background:A variety of therapy options are available for colorectal cancer,ranging from traditional medicine to complementary and alternative medicine.There is a growing body of evidence supporting the efficacy of co...Background:A variety of therapy options are available for colorectal cancer,ranging from traditional medicine to complementary and alternative medicine.There is a growing body of evidence supporting the efficacy of complementary and alternative medicine.Therefore,the main aim of this study is to conduct a scoping evaluation of traditional and herbal medicine’s effectiveness as an additional therapy for colorectal cancer patients in clinical settings.Methods:A systematic search was conducted for all articles pertaining to clinical trials related to traditional herbal medicine(THM)with or without other treatments,such as chemotherapy,placebos,or other types of treatment,published from 2010 to November 13,2020,using four search engines,namely Medline,Web of Science,Cochrane Library,and Scopus.Results:The number of colorectal cancer patients in five trials ranged from 89 to 565 people.The THMs stated in these studies were catalpol(Rehmannia glutinosa extract),the traditional Japanese medicine Daikenchuto(mixture of herbal extracts)and Goshajinkigan,Chinese patent herbal medicine Aidi injection,and the traditional Chinese medicine Simo decoction.Positive results were reported in term of reduction of colorectal cancer tumour marker(by catalpol),improvement of gastrointestinal function following gastrointestinal surgery(by Daikenchuto and Simo decoction),better disease control rate and quality of life score(by combination of Aidi injection and chemotherapy),and a decrease in the incidence of oxaliplatin-induced peripheral neurotoxicity(Goshajinkigan).Conclusion:All studies demonstrated fewer adverse effects found in THM intervention groups,however,evidence pointing to THMs’favourable effects on colorectal cancer patients is still required.Therefore,researchers and clinicians are encouraged to perform more research in this area so that more evidence of THM’s efficacy and safety in clinical settings can be obtained.展开更多
基金Supported by Grant from Tsumura and Co, the pharmaceutical company
文摘AIM: To evaluate the clinical usefulness of Daikenchuto (DKT) in hepatecomized patients. METHODS: Twenty patients were enrolled with informed consent. Two patients were excluded because of cancelled operations. The remaining 18 patients were randomly chosen for treatment with DKT alone or combination therapy of DKT and lactulose (n = 9, each group). Data were prospectively collected. Primary end points were Visual Analogue Scale (VAS) score for abdominal bloating, total Gastrointestinal Symptoms Rating Scale (GSRS) score for abdominal symptoms, and GSRS score for abdominal bloating. RESULTS: The VAS score for abdominal bloating and total GSRS score for abdominal symptoms recovered to levels that were not significantly different to preoperative levels by 10 d postoperation. Combination therapy of DKT and lactulose was associated with a significantly poorer outcome in terms of VAS and GSRS scores for abdominal bloating, total GSRS score, and total daily calorie intake, when compared with DKT alone therapy. CONCLUSION: DKT is a potentially effective drug for postoperative management of hepatectomized patients, not only to ameliorate abdominal bloating, but also to promote nutritional support by increasing postoperative dietary intake.
文摘Background:A variety of therapy options are available for colorectal cancer,ranging from traditional medicine to complementary and alternative medicine.There is a growing body of evidence supporting the efficacy of complementary and alternative medicine.Therefore,the main aim of this study is to conduct a scoping evaluation of traditional and herbal medicine’s effectiveness as an additional therapy for colorectal cancer patients in clinical settings.Methods:A systematic search was conducted for all articles pertaining to clinical trials related to traditional herbal medicine(THM)with or without other treatments,such as chemotherapy,placebos,or other types of treatment,published from 2010 to November 13,2020,using four search engines,namely Medline,Web of Science,Cochrane Library,and Scopus.Results:The number of colorectal cancer patients in five trials ranged from 89 to 565 people.The THMs stated in these studies were catalpol(Rehmannia glutinosa extract),the traditional Japanese medicine Daikenchuto(mixture of herbal extracts)and Goshajinkigan,Chinese patent herbal medicine Aidi injection,and the traditional Chinese medicine Simo decoction.Positive results were reported in term of reduction of colorectal cancer tumour marker(by catalpol),improvement of gastrointestinal function following gastrointestinal surgery(by Daikenchuto and Simo decoction),better disease control rate and quality of life score(by combination of Aidi injection and chemotherapy),and a decrease in the incidence of oxaliplatin-induced peripheral neurotoxicity(Goshajinkigan).Conclusion:All studies demonstrated fewer adverse effects found in THM intervention groups,however,evidence pointing to THMs’favourable effects on colorectal cancer patients is still required.Therefore,researchers and clinicians are encouraged to perform more research in this area so that more evidence of THM’s efficacy and safety in clinical settings can be obtained.
